Related Experiment Video
Updated: Oct 1, 2026

Assessing Respiratory Immune Responses to Haemophilus Influenzae
Published on: June 29, 2021
[A three-year review of acute respiratory tract infections caused by Streptococcus milleri group]
Rei Fujiki1, Tomotaka Kawayama, Toru Rikimaru
1Social Insurance Tagawa Hospital.
Abstract:
The objective of our study is to understand the clinical features of patients with acute respiratory tract infection associated with Streptococcus milleri group (SMG). Fifteen patients with SMG respiratory tract infection visited our hospital from July, 1997 through May, 2000. There were seven cases of pneumonia, two pulmonary abscess, three thoracic empyema and three acute bronchitis. The mean age of the patients was 57.8 years (range 16-87), twelve were males, and seven were smokers. The moderately to severe underlying diseases existed in thirteen patients (86.7%) and included the following: respiratory diseases (20.0%), history of the esophageal or gastric surgery (26.7%), central nerve system diseases (13.3%), alcohol intake (60.0%), hepatitis and pancreatitis (33.3%), diabetes mellitus (13.3%) and malignancy (6.7%). The species of SMG detected were as follows: S. constellatus, 8, S. anginosus, 6 and S. intermedius, 1. Anaerobic organism and other microorganisms were detected in five patients. A patient with SMG nosocominal pneumonia who previously had thoracic surgery for esophageal cancer died. Antibiotics therapy with carbapenem or combination therapy, drainage and no surgery, were successful in 14 of the 15 cases (93.3%). The number of intermediately or complete resistant strains against penicillin G, ampicillin and cefmetazole were 5 (33.3%), 8 (53.3%) and 12 (80.0%), respectively in this series. Recently, it is seemed that acute respiratory tract infections caused by SMG are increasing in the patients with moderately to severe underlying diseases, and several clinical strains of SMG are acquiring a tolerance to antibiotics.
Insights
Streptococcus milleri group (SMG) infections cause severe respiratory issues, particularly in patients with underlying conditions. Prompt antibiotic treatment and drainage are effective, but antibiotic resistance is a growing concern.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Pulmonology
Context:
- The Streptococcus milleri group (SMG) comprises bacteria frequently implicated in various infections.
- Respiratory tract infections (RTIs) caused by SMG can be severe, especially in immunocompromised or comorbid patients.
- Understanding the clinical spectrum and antimicrobial susceptibility of SMG RTIs is crucial for effective management.
Purpose:
- To elucidate the clinical characteristics of acute respiratory tract infections associated with the Streptococcus milleri group (SMG).
- To identify predisposing factors, common SMG species, and clinical outcomes in patients with SMG-related RTIs.
- To assess the antimicrobial resistance patterns of SMG strains isolated from respiratory infections.
Summary:
- Fifteen patients with SMG RTIs (pneumonia, abscess, empyema, bronchitis) were analyzed, with a mean age of 57.8 years; 86.7% had moderate to severe underlying diseases.
- The most common SMG species were S. constellatus (8), S. anginosus (6), and S. intermedius (1).
- Treatment involving antibiotics (carbapenem or combination therapy), drainage, and conservative management achieved a 93.3% success rate, though significant resistance to penicillin G, ampicillin, and cefmetazole was observed.
Impact:
- This study highlights the increasing prevalence of SMG RTIs in patients with significant comorbidities.
- It underscores the importance of considering SMG in the differential diagnosis of severe RTIs.
- The findings emphasize the emerging challenge of antibiotic resistance within SMG, necessitating careful treatment strategies and ongoing surveillance.
Related Concept Videos
Microbiota of the Respiratory Tract
Pneumonia III: Complications and Assessment
Streptococcal Pharyngitis
Atypical Pneumonia
Rheumatic Heart Disease III: Medical Management
Mitral Stenosis III: Medical Management

